Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation

Antiviral Therapy

Volumn 13, Issue 7, 2008, Pages 901-907

  Boffito, Marta ^a   Else, Laura ^b   Back, David ^b   Taylor, Jessica ^a   Khoo, Saye ^b   Sousa, Marta ^a   Pozniak, Anton ^a   Gazzard, Brian ^a   Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EYE JAUNDICE; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RITONAVIR; TREATMENT OUTCOME;

EID: 56749158797     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
2. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2:105-113.
3. Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects: the CASTLE study, 48-week results. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 37.
4. Swainston Harrison T, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005; 65:2309-2336.
5. Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006; 66:1275-1299.
6. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naïve HIV-1-infected patients at week 48: ARTEMIS. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract H-718b.
7. Mildvan D, Tierney C, Gross R, et al. Randomized comparison in treatment-naive patients of once-daily vs twice-daily lopinavir/ ritonavir-based ART and comparison of once-daily self-administered vs directly observed therapy. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 138.
8. Boffito M, Hill A. Effect of protease inhbitors on ritonavir pharmacokinetics. 8th International Workshop on Clinical Pharmacology of HIV Therapy. 16-18 April 2007, Budapest, Hungary. Abstract 50.
9. Cohen CJ, Morris A, Bazner S, et al. The FOTO study: a pilot study of short-cycle treatment interruption, taking antiretroviral medications for five days on, two days off (FOTO), for those with viral load suppression on either PI or EFV-based regimens. XV International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract TuPeB4575.
10. Dickinson L, Robinson L, Tjia J, Khoo S, Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829:82-90.
11. La Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3:4-14.
12. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:65-72.
13. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
14. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
15. Taylor S, Boffito M, Khoo S, Smit E, Back D. Stopping antiretroviral therapy. AIDS 2007; 21:1673-1682.
16. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected patients. Curr Opin HIV AIDS 2008; 3:296-305.
17. Reyataz® (atazanavir). Package insert 2007. Bristol-Myers Squibb, Princeton, NJ, USA.
18. Reyataz® (atazanavir). Summary of product characteristics 2007. Bristol-Myers Squibb, Uxbridge, UK.
19. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18:1291-1297.
20. González de Requena D, Bonora S, Garazzino S, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49:3966-3969.
21. Kempf D, King M, Bauer E, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy. 10th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 600.